Infex Awarded Biomedical Catalyst Grant For COV-X Project

Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18…

COVID-19 Pandemic Triggers Upsurge in MBL Infections

New research has discovered that the ongoing COVID-19 pandemic has triggered a significant upsurge in metallo-β-lactamase (MBL)……

CARB-X Receives Additional $370m from U.S. Government and Wellcome

Enables continued investment in innovative projects to tackle the growing global threat posed by AMR

Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism

Infex Therapeutics, one of the UK’s leading infectious disease biotech companies, has today lauded the conclusions of a NHS England and the…

Infex scientists achieve breakthrough to overcome critical priority drug resistant infections

One of the UK’s leading infectious disease biotech companies has announced a breakthrough in an antimicrobial resistance (AMR) program that…

Infex agrees partnership with Colibri Scientific to provide services for RESP-X program

Infex Therapeutics has today announced a deal with Colibri Scientific, to provide logistics and sample operational services for Infex’s…

Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains

One of the UK’s leading infectious disease biotech companies has announced a breakthrough in laboratory trials of a new drug to treat…

Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics

“The announcement today that the government is increasing public R&D investment to record levels to cement the UK as a global science and…

Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership

Infex Therapeutics is pressing ahead with a major development of its pandemic resilience strategy by today announcing an agreement with…